repotrectinib
Bms
['trident-1', 'lung', 'trident', 'nsclc', 'sclc', 'repotrectinib']
#asco23 | hall d1 | sund 4:42pm ct
intracranial and systemic efficacy of repotrectinib in advanced ros1 fusion-positive (ros1+) non-small cell lung cancer (nsclc) and central nervous system metastases (cns mets) in the phase 1/2 trident-1 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.